Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Successful Engraftment, Increased Hemoglobin, and Reduced Transfusion Dependence in Patients with Transfusion-Dependent Beta-Thalassemia Treated in the Edithal Trial

Haydar Frangoul, Rabi Hanna, Mark C. Walters, Kai-Hsin Chang, Michael Jaskolka, Keunpyo Kim, Baisong Mei, Olubunmi Afonja, Alexis Thompson

Blood (2024) 144 (Supplement 1): 7456.

https://doi.org/10.1182/blood-2024-208623

Published: 2024

Journal Articles

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Daniel P. Nurse, Wei Wei, Amanda Burns, Joseph Farinella, Deepa Jagadeesh, Robert M. Dean, Rabi Hanna, Seth J Rotz, Aaron T. Gerds, Claudio Brunstein, Matt Kalaycio, Craig S. Sauter, Betty K. Hamilton, Ronald Sobecks

Blood (2024) 144 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2024-202626

Published: 2024

Journal Articles

Time Is Quality of Life (QoL): An Institutional Review of Emergency Department Management of Acute Vaso-Occlusive Episodes in Patients with Sickle Cell Disease

Jaime Baldeon Mendoza, Consuela Albright, Kristin Seastrand, Katrina Seedhouse, Rosa Young, Milvon Bryson, Ravi Talati, Rabi Hanna, Crawford John Strunk

Blood (2024) 144 (Supplement 1): 7530.

https://doi.org/10.1182/blood-2024-207564

Published: 2024

Journal Articles

Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration

Blood (2024) 144 (Supplement 1): 2691.

https://doi.org/10.1182/blood-2024-198302

Published: 2024

Journal Articles

Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial

Rabi Hanna, Haydar Frangoul, Christopher McKinney, Luis Pineiro, Markus Mapara, Jignesh Dalal, Hemalatha Rangarajan, Harold Atkins, Kai-Hsin Chang, Baisong Mei, Olubunmi Afonja, Mark C. Walters

Blood (2024) 144 (Supplement 1): 4955.

https://doi.org/10.1182/blood-2024-210343

Published: 2024

Journal Articles

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Blood (2024) 143 (25): 2654–2665.

https://doi.org/10.1182/blood.2023023301

Published: 2024

Includes: Supplemental data

Journal Articles

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Blood (2023) 142 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2023-192022

Published: 2023

Journal Articles

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Ronald Sobecks, Hong Li, Danielle Cenin, Seema Patel, Jesse Edwards, Stephanie Farlow, Amelia Bragg, Rabi Hanna, Seth J Rotz, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Brad Pohlman, Betty K. Hamilton, Claudio Brunstein, Matt Kalaycio, Craig S Sauter

Blood (2023) 142 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2023-187071

Published: 2023

Journal Articles

AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Rabi Hanna, Haydar Frangoul, Christopher McKinney, Luis Pineiro, Markus Mapara, Jignesh Dalal, Kai-Hsin Chang, Michael Jaskolka, Keunpyo Kim, Daphne L. Farrington, Maha Wally, Baisong Mei, Adebayo Lawal, Olubunmi O. Afonja, Mark C. Walters

Blood (2023) 142 (Supplement 1): 4996.

https://doi.org/10.1182/blood-2023-187397

Published: 2023

Journal Articles

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

Sarah Nikiforow, Mitchell Horwitz, John M. McCarty, Anum Abbas, James M. Coghill, Jenny Stanton, Julie Ma, Spyridoula Vasileiou, Sarah Gilmore, Bhagirathbhai Dholaria, Rabi Hanna, Randy Taplitz, Rajat Bansal

Blood (2023) 142 (Supplement 1): 6889.

https://doi.org/10.1182/blood-2023-189708

Published: 2023

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 2383–2385.

https://doi.org/10.1182/blood-2022-165229

Published: 2022

Journal Articles

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 10462–10464.

https://doi.org/10.1182/blood-2022-170552

Published: 2022

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Blood (2021) 138 (Supplement 1): 3880.

https://doi.org/10.1182/blood-2021-148652

Published: 2021

Journal Articles

Successful Treatment with ALVR105 for Disseminated Adenovirus Infection in an Infant after Allogeneic Hematopoietic Cell Transplantation: A Case Report

Nikki Agarwal, Seth J Rotz, Seung Hyun Moon, Rabi Hanna

Blood (2021) 138 (Supplement 1): 4865.

https://doi.org/10.1182/blood-2021-150595

Published: 2021

Journal Articles

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Betty K. Hamilton, Lisa A. Rybicki, Taylor Lucas, Donna Corrigan, Matt Kalaycio, Rabi Hanna, Seth J Rotz, Robert M. Dean, Aaron T. Gerds, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Edward A. Copelan, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 99.

https://doi.org/10.1182/blood-2021-149686

Published: 2021

Journal Articles

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Blood (2021) 138 (16): 1429–1440.

https://doi.org/10.1182/blood.2021011719

Published: 2021

Includes: Supplemental data

Journal Articles

Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Sanghee Hong, MD, Lisa Rybicki, MS, Linda McLellan, LISW, Jane Dabney, LISW-S, Aaron T. Gerds, MDMS, Seth J Rotz, MD, Matt Kalaycio, MD, Rabi Hanna, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Ronald Sobecks, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-138939

Published: 2020

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Adetola A. Kassim, MDMS, Josu de la Fuente, Ali Debsan Alahmari, MBBS, MD MNAMS, Michael J. Eckrich, MD MPH, Rabi Hanna, MD, Nathalie Dhedin, MD, Biljana N. Horn, MD, Vandy Black, MDMSc, Roseane V Gouveia, Adriana Seber, MDMS, Belinda Pinto Simões, MD PhD, Thalita Cristina de Mello Costa, MD, Renato Guerino-Cunha, Carmem M. S. Bonfim, MDPhD, Roberto Luiz da Silva, Nelson Hamerschlak, MD PhD, Juliana Folloni Fernandes, MD, Michael Kent, MDBS, Satya Prakash Yadav, MBBS, MD, Erfan Nur, MDPhD, Mohsen Alzahrani, Ben Carpenter, PhD, William Tse, MD, Maria Isabel, Hemalatha G Rangarajan, MD, Ibrahim Ahmed, MD, Adeseye Michael Akinsete, MBBS, Courtney D. Fitzhugh, MD, Kathryn A. Culos, PharmD, Leena Karnik, FRCPath, MRCP, James Connelly, MD, Carrie Kitko, MD, Jennifer Andrews, MDMSc, Karina L Wilkerson, NP, MSN, Robert Brodsky, Tatsuki Koyama, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-141771

Published: 2020

Journal Articles

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Filippo Milano, MD PhD, Andrew R Rezvani, MD, Joanne Kurtzberg, MD, Chatchada Karanes, MD, Jonathan A Gutman, MD, Christine Duncan, MD, Alla Keyzner, MD, Rabi Hanna, MD, Tonya Kimberly Marmon, PhD, Ann Dahlberg, MD, Colleen Delaney, MD MSc

Blood (2019) 134 (Supplement_1): 146.

https://doi.org/10.1182/blood-2019-130716

Published: 2019

Journal Articles

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 4599.

https://doi.org/10.1182/blood-2019-131011

Published: 2019

NARROW

Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Successful Engraftment, Increased Hemoglobin, and Reduced Transfusion Dependence in Patients with Transfusion-Dependent Beta-Thalassemia Treated in the Edithal Trial

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Time Is Quality of Life (QoL): An Institutional Review of Emergency Department Management of Acute Vaso-Occlusive Episodes in Patients with Sickle Cell Disease

Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration

Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Successful Treatment with ALVR105 for Disseminated Adenovirus Infection in an Infant after Allogeneic Hematopoietic Cell Transplantation: A Case Report

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only